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Introduction {#phy213238-sec-0001}
============

Older adults are at greater risk of heat‐related injuries (e.g., heat syncope and heat stroke), likely due to attenuated cardiovascular and thermoregulatory function relative to their younger counterparts (Worfolk [2000](#phy213238-bib-0050){ref-type="ref"}; Kenney et al. [2014](#phy213238-bib-0021){ref-type="ref"}; Kenny et al. [2016a](#phy213238-bib-0025){ref-type="ref"}). In parallel, although nitric oxide (NO) synthase (NOS) is known to contribute to the regulation of cutaneous vasodilation (Kellogg et al. [1998](#phy213238-bib-0020){ref-type="ref"}; Shastry et al. [2000](#phy213238-bib-0040){ref-type="ref"}; Welch et al. [2009](#phy213238-bib-0048){ref-type="ref"}; Fujii et al. [2014b](#phy213238-bib-0009){ref-type="ref"}; McNamara et al. [2014](#phy213238-bib-0029){ref-type="ref"}) and sweating (Welch et al. [2009](#phy213238-bib-0048){ref-type="ref"}; Fujii et al. [2014b](#phy213238-bib-0009){ref-type="ref"}; Stapleton et al. [2014](#phy213238-bib-0045){ref-type="ref"}; Louie et al. [2016](#phy213238-bib-0027){ref-type="ref"}) during heat stress in young adults, these contributions are diminished in older adults (Stanhewicz et al. [2013](#phy213238-bib-0044){ref-type="ref"}; Stapleton et al. [2014](#phy213238-bib-0045){ref-type="ref"}; Fujii et al. [2015b](#phy213238-bib-0011){ref-type="ref"}, [2016b](#phy213238-bib-0013){ref-type="ref"}). As a potential mechanism, aging is known to increase the level of reactive oxygen species (i.e., oxidative stress) such as superoxide (Durrant et al. [2009](#phy213238-bib-0005){ref-type="ref"}), which can reduce NO bioavailability (Fujii et al. [2014a](#phy213238-bib-0008){ref-type="ref"}). Hence, in older adults, the nonselective antioxidant ascorbate may improve cutaneous vasodilation and sweating via NOS‐dependent mechanisms during heat stress, such as that which occurs during exercise in the heat.

Individuals with type 2 diabetes mellitus are at increased risk of heat‐related injuries (Semenza et al. [1999](#phy213238-bib-0039){ref-type="ref"}; Kenny et al. [2016b](#phy213238-bib-0026){ref-type="ref"}). This is likely secondary to an attenuation in whole‐body heat dissipation (Kenny et al. [2013](#phy213238-bib-0023){ref-type="ref"}) associated with reductions in local cutaneous vasodilation (Wick et al. [2006](#phy213238-bib-0049){ref-type="ref"}; Sokolnicki et al. [2009](#phy213238-bib-0042){ref-type="ref"}) and sweating (Fealey et al. [1989](#phy213238-bib-0006){ref-type="ref"}; Petrofsky et al. [2005](#phy213238-bib-0035){ref-type="ref"}); albeit due to regional heterogeneity, reductions in local heat loss responses are not always observed (Kenny et al. [2013](#phy213238-bib-0023){ref-type="ref"}, [2016b](#phy213238-bib-0026){ref-type="ref"}). Individuals with type 2 diabetes have been shown to have increased oxidative stress relative to healthy older adults without type 2 diabetes (Folli et al. [2011](#phy213238-bib-0007){ref-type="ref"}; Casoinic et al. [2016](#phy213238-bib-0003){ref-type="ref"}; Restaino et al. [2016](#phy213238-bib-0037){ref-type="ref"}), which as mentioned above, may result in attenuations in the heat loss responses via mechanisms related to NO. Ascorbate may therefore augment the heat loss responses during exercise in the heat in older adults with type 2 diabetes to a greater extent compared to healthy older adults.

This study evaluated the effect of local ascorbate administration on the regulation of cutaneous vasodilation and sweating response during exercise in the heat in older adults with and without type 2 diabetes. We hypothesized that reducing oxidative stress improves the heat loss responses of cutaneous vasodilation and sweating by increasing NOS‐derived NO in both healthy older adults and those with type 2 diabetes during exercise in the heat, with the latter group experiencing comparatively greater improvements.

Materials and Methods {#phy213238-sec-0002}
=====================

Ethical approval {#phy213238-sec-0003}
----------------

This study was approved by the University of Ottawa Health Sciences and Science Research Ethics Board and adhered to the guidelines set forth by the *Declaration of Helsinki*. Verbal and written informed consent was acquired from all volunteers before the initiation of any experimental procedures.

Participants {#phy213238-sec-0004}
------------

Twelve older males diagnosed with type 2 diabetes mellitus (T2D) for at least 5 years and twelve healthy nondiabetic older males (Control) participated in this study. All participants were free of respiratory disease, heart disease, uncontrolled hypertension, and neuropathy. Participant characteristics are described in Table [1](#phy213238-tbl-0001){ref-type="table-wrap"}. All participants with T2D were taking the following medications (number of subjects are indicated in parenthesis): metformin (12), statin (6), dipeptidyl peptidase‐4 inhibitor (6), sulfonylurea (6), angiotensin converting enzyme inhibitor (4), acetylsalicylic acid (4), insulin (3), angiotensin receptor blocker (3), calcium channel blocker (2), sodium/glucose cotransporter 2 inhibitor (1), beta‐blocker (1), and diuretic (1). All subjects in the Control group were without prescription medications. All participants were nonsmoking for at least 5 years.

###### 

Participant characteristics

                                 Control group   T2D group
  ------------------------------ --------------- -----------------------------------------------------
  Number of participants         12              12
  Age (years)                    64 ± 7          61 ± 9
  Height (m)                     1.75 ± 0.05     1.70 ± 0.06[a](#phy213238-note-0003){ref-type="fn"}
  Body mass (kg)                 83.0 ± 8.5      87.5 ± 18.7
  Body surface area (m^2^)       1.99 ± 0.11     1.98 ± 0.22
  Body fat (%)                   31 ± 6          30 ± 6
  Peak oxygen uptake (L/min)     2.6 ± 0.3       2.3 ± 0.5
  (mL/kg/min)                    31.9 ± 4.2      27.0 ± 4.8[a](#phy213238-note-0003){ref-type="fn"}
  HbA~1C~ (%)                    --              7.4 ± 1.1
  Duration of diabetes (years)   n/a             7.5 ± 4.4

All values are expressed as mean ± standard deviation. T2D, type 2 diabetes. HbA~1C~, hemoglobin A~1c~. n/a, not applicable.

versus Control group (*P* ≤ 0.05).

John Wiley & Sons, Ltd

Experimental design {#phy213238-sec-0005}
-------------------

All participants completed one preliminary and one experimental session on separate days. Participants were asked to refrain from consuming alcohol, caffeine, and heavy exercise at least 12 h prior to the start of the sessions. On the day of each session, participants were allowed to have food 2 h before the experiment. Experimental trials were performed at different periods during the day depending on individual schedules. During the preliminary session, body mass, height, body surface area, body fat, and peak oxygen uptake were determined. Body height was measured using a stadiometer (Model 2391, Detecto Scale Company, Webb City, MO), and body mass was measured by a digital weight scale platform (model CBU150X, Mettler Toledo Inc., Mississauga, ON, Canada). Body surface area was calculated using body mass and height (DuBois and DuBois [1916](#phy213238-bib-0004){ref-type="ref"}). Hydrostatic weighing was used to estimate body fat percentage (Siri [1956](#phy213238-bib-0041){ref-type="ref"}). Peak oxygen uptake on a semirecumbent cycle ergometer (Corival Recumbent, Lode B.V., Groningen, Netherlands) was evaluated using an automated indirect calorimetry system (Medgraphics Ultima, Medical Graphics Corporation, St Paul, MN) as previously reported (Fujii et al. [2016a](#phy213238-bib-0012){ref-type="ref"}).

On the day of the experimental session, body mass was measured then participants changed into shorts and running shoes. Thereafter, participants were transferred to a thermoneutral room (\~23°C) where they were seated in a semirecumbent position and were instrumented with four microdialysis fibers (MD2000, Bioanalytical Systems, West Lafayette, IN) in the dermal layer of the skin on the dorsal side of the left forearm. These fibers have a semipermeable membrane (30 kDa cutoff, 10 mm), through which pharmacological agents can be continuously delivered into the dermis, ultimately affecting skin vessels and sweat glands. In order to situate the fibers subcutaneously, a 25‐gauge needle was inserted into the skin using aseptic technique. The entry and exit points of fiber insertion were separated by \~2.5 cm. The microdialysis fiber was then threaded through the lumen of the needle, after which the needle was withdrawn leaving the fiber in place. The location of each microdialysis fiber was separated by 2--4 cm.

Once all four fibers were placed in the skin, each microdialysis site was perfused with lactated Ringer (Baxter, Deerfield, IL) at a constant rate of 4 *μ*L/min with a micro‐infusion pump (Model 400, CMA Microdialysis, Solna, Sweden) for approximately 30 min. Thereafter, the participants moved to a thermal chamber (Can‐Trol Environmental Systems Limited, Markham, ON, Canada) regulated to an ambient air temperature of 35°C and a relative humidity of 20% where they rested on a semirecumbent cycle ergometer (Corival Recumbent, Lode B.V.) and perfusion of pharmacological agents through each microdialysis fiber began. The four sites were continuously perfused in a counterbalanced manner with either (1) lactated Ringer (Baxter, Deerfield, IL, US) (vehicle control), (2) 10 mmol/L ascorbate, a known antioxidant (Sigma‐Aldrich, St. Louis, MO), (3) 10 mmol/L *N* ^G^‐nitro‐~L~‐arginine methyl ester (~L~‐NAME), a nonselective NOS inhibitor (Sigma‐Aldrich), or (4) a combination of 10 mmol/L ascorbate and 10 mmol/L ~L~‐NAME (ascorbate + ~L~‐NAME). These concentrations were determined based on previous studies in which intradermal microdialysis was employed in human skin (Holowatz and Kenney [2007](#phy213238-bib-0017){ref-type="ref"}; Stewart et al. [2008](#phy213238-bib-0046){ref-type="ref"}; Yamazaki [2010](#phy213238-bib-0051){ref-type="ref"}; Medow et al. [2011](#phy213238-bib-0032){ref-type="ref"}; Fujii et al. [2015a](#phy213238-bib-0010){ref-type="ref"}; Meade et al. [2015](#phy213238-bib-0030){ref-type="ref"}). Each infusion was performed at a constant rate of 4.0 *μ*L/min for at least 60 min prior to data collection to ensure action of each drug. Furthermore, \~90 min elapsed between fiber insertion and the beginning of baseline data collection (30 min of lactated Ringer infusion at all sites + 60 min drug perfusion), a period of time sufficient to ensure that any tissue redness associated with fiber insertion had subsided (Anderson et al. [1994](#phy213238-bib-0001){ref-type="ref"}). Since this drug infusion was performed in the heat (35°C), the participants were pre‐exposed to a sufficiently prolonged ambient heat stress prior to data collection. As such, we were also able to assess the influence of a passive heat stress on heat loss responses which has been shown to be attenuated in older adults with (Kenny et al. [2016a](#phy213238-bib-0025){ref-type="ref"}) and without type 2 diabetes (Kenny et al. [2015](#phy213238-bib-0024){ref-type="ref"}) relative to young adults.

After the \>60 min drug infusion period, 10‐min of baseline resting measurements were taken in the heat (35°C). Thereafter, the participants completed two 30‐min bouts of cycling at a fixed rate of metabolic heat production of \~500 W (Control: 480 ± 32; T2D: 500 ± 7 W; *P* = 0.12). A fixed heat load was employed to ensure a similar thermal drive, and therefore stimulus for sweating, between individuals (Gagnon et al. [2013](#phy213238-bib-0014){ref-type="ref"}). This resulted in a similar exercise intensities as defined by %peak oxygen uptake in the Control and T2D groups of 68 ± 4 and 72 ± 5%, respectively (*P* = 0.22). The first and second bouts of exercise were followed by 20‐ and 40‐min recovery periods. In this study we employed two bouts of exercise in order to evaluate the mechanisms underpinning the regulation of heat loss responses during and following successive exercise cycles. Studies show that the heat loss responses are rapidly attenuated in the first 15‐min following cessation of exercise despite progressive increases in body core temperature with successive exercise bouts. However, the heat loss responses are activated more quickly in subsequent exercise bouts. These differences have been shown to have an important effect on body core temperature regulation. We employed a longer 40‐min recovery period following the second exercise bout to ensure that stable values had been achieved. Following the second 40‐min recovery period, 50 mmol/L sodium nitroprusside (Sigma‐Aldrich) was administered at all four microdialysis sites at a rate of 6.0 *μ*L/min for 20--30 min in order to achieve maximal cutaneous vasodilation. Thereafter, all equipment were removed, and post‐experiment body mass was recorded.

Measurements {#phy213238-sec-0006}
------------

We employed the 1.1 cm^2^ ventilated sweat capsule which was designed for the evaluation of local forearm sweat rate when employing intradermal microdialysis (Meade et al. [2016](#phy213238-bib-0031){ref-type="ref"}). Local sweat rate was estimated based on sweat production evaluated under the sweat capsules, which were positioned over the center of each microdialysis membrane and affixed to the skin with adhesive rings and topical skin glue (Collodion HV, Mavidon Medical products, Lake Worth, FL). To evaporate all sweat produced under the capsule, dry compressed air from gas tanks located in the thermal chamber was supplied to each capsule at a constant rate. The water content of the effluent air was measured with a capacitance hygrometer (Model HMT333, Vaisala, Helsinki, Finland). Local forearm sweat rate was calculated every 5 sec using the difference in humidity between influent and effluent air, multiplied by the flow rate, and normalized to the skin surface area under the capsule (mg/min/cm^2^).

Cutaneous red blood cell flux, expressed in perfusion units (index of cutaneous blood flow), was locally measured at a sampling rate of 32 Hz with laser‐Doppler flowmetry (PeriFlux System 5000, Perimed, Stockholm, Sweden). An integrated laser‐Doppler flowmetry probe with a 7‐laser array (Model 413, Perimed) was placed in the center of each sweat capsule directly over each microdialysis fiber. Systolic and diastolic blood pressures were measured by manual auscultation using a mercury column sphygmomanometer (Baumanometer Standby Model, WA Baum Co, Copiague, NY). Mean arterial pressure was calculated as diastolic arterial pressure plus one‐third the difference between systolic and diastolic pressures (pulse pressure). Cutaneous vascular conductance (CVC) was calculated as cutaneous red blood cell flux divided by mean arterial pressure. CVC data were normalized at each site as percentage of maximum (expressed as %CVCmax). Maximum CVC was obtained during the administration of sodium nitroprusside at the end of the experiment. Heart rate was recorded every 5 sec using a heart rate monitor (RS400, Polar Electro, Kempele, Finland).

Body core temperature was measured using a thermocouple temperature probe (Mon‐a‐therm, Mallinckrodt Medical, St Louis, MO) inserted in the esophagus or rectum. For participants unable to tolerate the insertion of these probes, a temperature sensor (Braun ThermoScan PRO 6000, Welch Allyn, Skaneateles Falls, New York) inserted in the aural canal was employed to estimate body core temperature. Skin temperature was measured using thermocouples (Concept Engineering, Old Saybrook, CT) attached to the skin with adhesive rings and surgical tape. Mean skin temperature was estimated as a weighted mean value using local skin temperatures measured at four sites (20% calf, 20% quadriceps, 30% biceps, and 30% chest) according to the equation used by Hardy and Dubois ([1938](#phy213238-bib-0016){ref-type="ref"}). Esophageal, rectal, and skin temperature data were sampled at 15 sec intervals using a data acquisition module (Model 34970A; Agilent Technologies Canada Inc., Mississauga, ON, Canada) and simultaneously displayed and recorded in spreadsheet format on a personal computer with LabVIEW software (Version 7.0, National Instruments, Austin, TX). Aural canal temperature was recorded every 5 min.

Metabolic rate was determined using indirect calorimetry (MOXUS system, Applied Electrochemistry, Pittsburgh, PA) where expired gases were analyzed for oxygen and carbon dioxide concentrations. Approximately 20 min before the start of baseline resting data collection, gas mixtures of known concentrations were used to calibrate gas analyzers and a 3 L syringe was used to calibrate the turbine ventilometer. The subjects wore full face masks (Model 7600 V2, Hans‐Rudolph, Kansas City, MO) attached to a 2‐way T‐shape nonrebreathing valve (Model 2700, Hans‐Rudolph). Oxygen uptake and respiratory exchange ratio were obtained every 30 sec and were used to calculate metabolic rate (Nishi [1981](#phy213238-bib-0034){ref-type="ref"}; Kenny and Jay [2013](#phy213238-bib-0022){ref-type="ref"}). Metabolic heat load was estimated as metabolic rate minus the external work (i.e., work rate during cycling).

For the safety of participants with type 2 diabetes, blood glucose concentration was monitored using a blood glucose meter (Contour Next, Bayer AG, Leverkusen, Germany).

Data analysis {#phy213238-sec-0007}
-------------

All data used for data analysis were obtained by averaging values over the last 5 min of each time period, with the exception of absolute maximal CVC (perfusion units^**.**^mmHg^−1^) obtained during sodium nitroprusside administration (peak values averaged over 2 min). The contribution of NOS to cutaneous vasodilation occurring during the last 5 min of each exercise bout was evaluated as the difference (∆) in CVC between the vehicle control and ~L~‐NAME sites. Similarly, the NOS contribution in the presence of ascorbate was also evaluated by ∆CVC between the vehicle control and ascorbate + ~L~‐NAME sites. Due to technical difficulties, the measurement of one CVC, heart rate, body core temperature, and percent body fat as well as three skin temperatures from the T2D group, and one body core temperature from the Control group were not acquired.

Statistical analysis {#phy213238-sec-0008}
--------------------

Local forearm CVC and sweat rate were analyzed using a three‐way mixed‐design analysis of variance with factors of treatment site (four levels: vehicle control, ascorbate, ~L~‐NAME, ascorbate + ~L~‐NAME), time (six levels: baseline, exercise 1, recovery 1, exercise 2, recovery 2 at 20 and 40 min), and group (two levels: Control and T2D). Body temperatures and cardiovascular variables were analyzed using a two‐way mixed‐design analysis of variance with factors of time (six levels) and group (two levels). Absolute maximal CVC (expressed in perfusion units/mmHg) attained during sodium nitroprusside infusion was analyzed using a two‐way mixed‐design analysis of variance with factors of treatment site (four levels) and group (two levels). When a significant interaction or main effect was observed, *post hoc* multiple comparisons were conducted using the modified Bonferroni procedures \[i.e., Holm procedure (Gordon and Salzman [2008](#phy213238-bib-0015){ref-type="ref"})\]. Student\'s pairwise and nonpairwise *t‐tests* were employed for between‐site and between‐group comparisons, respectively. The level of significance for all analyses was set at *P* ≤ 0.05, and all values are reported as mean ± 95% confidence interval, unless otherwise noted. All statistical tests were performed using the software package SPSS 24 for Windows (IBM, Armonk, NY).

Results {#phy213238-sec-0009}
=======

Participant characteristics {#phy213238-sec-0010}
---------------------------

Age, body mass, body surface area, body fat, and absolute peak oxygen uptake were not different between groups, whereas height and peak oxygen uptake relative to body mass were lower in the T2D group (Table [1](#phy213238-tbl-0001){ref-type="table-wrap"}).

Cutaneous vascular conductance {#phy213238-sec-0011}
------------------------------

Main effects of treatment site, time, and group, as well as an interaction between time and group were detected for CVC (Fig. [1](#phy213238-fig-0001){ref-type="fig"}, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}, all *P* ≤ 0.05). There was an interaction between treatment site and group for ∆CVC (Fig. [2](#phy213238-fig-0002){ref-type="fig"}, *P* = 0.02). No main effects of treatment site and group and their interaction were measured for absolute maximal CVC (Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}, all *P* \> 0.05).

![Cutaneous vascular conductance evaluated at the last 5 min of the first (Ex 1) and second (Ex 2) 30‐min exercise in older healthy adults (Control, panel A) and those with type 2 diabetes (T2D, panel B). Cutaneous vascular conductance was evaluated at four skin sites treated with either 1) lactated Ringer (vehicle control site), 2) ascorbate, an antioxidant, 3) ~L~‐NAME, a nitric oxide synthase inhibitor, or 4) ascorbate + ~L~‐NAME. Data are expressed as mean ± 95% confidence interval. \*, versus vehicle control site (*P* ≤ 0.05). †, versus Control group (*P* ≤ 0.05).](PHY2-5-e13238-g001){#phy213238-fig-0001}

###### 

Cutaneous vascular conductance measured during baseline rest (before exercise) and postexercise recovery periods as well as that evaluated during sodium nitroprusside administration (absolute maximum)

                         %CVC~max~                                         (Perfusion units/mmHg)                                                                                                                                                                            
  ---------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------- -------------
  Control group                                                                                                                                                                                                                                                              
  Vehicle control        36 ± 11                                           44 ± 9                                            45 ± 10                                                                                       39 ± 9                                            1.73 ± 0.40
  Ascorbate              40 ± 8                                            51 ± 7                                            51 ± 7                                                                                        51 ± 10                                           1.89 ± 0.43
  ~L~‐NAME               18 ± 5[a](#phy213238-note-0005){ref-type="fn"}    25 ± 6[a](#phy213238-note-0005){ref-type="fn"}    27 ± 9[a](#phy213238-note-0005){ref-type="fn"}                                                25 ± 7                                            1.70 ± 0.29
  Ascorbate + ~L~‐NAME   21 ± 7                                            28 ± 6[a](#phy213238-note-0005){ref-type="fn"}    25 ± 6[a](#phy213238-note-0005){ref-type="fn"}                                                27 ± 7                                            1.82 ± 0.43
  T2D group                                                                                                                                                                                                                                                                  
  Vehicle control        42 ± 6                                            57 ± 8[b](#phy213238-note-0006){ref-type="fn"}    59 ± 9[b](#phy213238-note-0006){ref-type="fn"}                                                53 ± 7[b](#phy213238-note-0006){ref-type="fn"}    2.02 ± 0.48
  Ascorbate              42 ± 7                                            56 ± 9                                            65 ± 5[b](#phy213238-note-0006){ref-type="fn"}                                                58 ± 8                                            1.97 ± 0.52
  ~L~‐NAME               30 ± 10[b](#phy213238-note-0006){ref-type="fn"}   46 ± 15[b](#phy213238-note-0006){ref-type="fn"}   47 ± 11[b](#phy213238-note-0006){ref-type="fn"}                                               41 ± 10[b](#phy213238-note-0006){ref-type="fn"}   1.68 ± 0.32
  Ascorbate + ~L~‐NAME   25 ± 5[a](#phy213238-note-0005){ref-type="fn"}    37 ± 11[a](#phy213238-note-0005){ref-type="fn"}   37 ± 8[a](#phy213238-note-0005){ref-type="fn"} ^,^ [b](#phy213238-note-0006){ref-type="fn"}   34 ± 9[a](#phy213238-note-0005){ref-type="fn"}    1.66 ± 0.40

All values are expressed as mean ± 95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period. Ascorbate, an antioxidant; ~L~‐NAME, a nitric oxide synthase inhibitor; Rec, recovery; T2D, type 2 diabetes; CVC, Cutaneous vascular conductance.

versus vehicle control site (*P* ≤ 0.05).

versus Control group (*P* ≤ 0.05).

John Wiley & Sons, Ltd

![Pharmacological treatment‐induced change (∆) in cutaneous vascular conductance from lactated Ringer site (vehicle control site) in older healthy adults (Control, panel A) and those with type 2 diabetes (T2D, panel B). Cutaneous vascular conductance measured at the last 5 min of the first (Ex 1) and second (Ex 2) 30‐min exercise was used for data analysis. Pharmacological treatments employed were 1) ~L~‐NAME, a nitric oxide synthase inhibitor, or 2) ascorbate (an antioxidant) + ~L~‐NAME. Data are expressed as mean ± 95% confidence interval. †, versus Control group (*P* ≤ 0.05).](PHY2-5-e13238-g002){#phy213238-fig-0002}

### Control group {#phy213238-sec-0012}

In the Control group, independent infusion of ascorbate did not affect CVC relative to the vehicle control site at any time point (all *P* \> 0.05, Fig. [1](#phy213238-fig-0001){ref-type="fig"}A and Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). In contrast, ~L~‐NAME reduced CVC in comparison to the vehicle control site throughout the experiment (all *P* ≤ 0.05) with the exception of at 40 min into second recovery period, where CVC tended (*P* = 0.07) to be lower at the ~L~‐NAME relative to vehicle control site (Fig. [1](#phy213238-fig-0001){ref-type="fig"}A, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). Combined infusion of ascorbate and ~L~‐NAME also attenuated CVC relative to the vehicle control site during the second exercise and first recovery as well as the first 20‐min of the second recovery period (all *P* ≤ 0.05, Fig. [1](#phy213238-fig-0001){ref-type="fig"}A, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). The magnitude of reduction in CVC (∆CVC) induced by ~L~‐NAME during exercise was similar with and without co‐administration of ascorbate (Fig. [2](#phy213238-fig-0002){ref-type="fig"}A).

### T2D group {#phy213238-sec-0013}

In the T2D group, administration of ascorbate did not affect CVC in comparison to the vehicle control site at any time point (all *P* ≤ 0.05, Fig. [1](#phy213238-fig-0001){ref-type="fig"}B, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). ~L~‐NAME attenuated CVC in relation to the vehicle control site during each exercise bout (all *P* ≤ 0.05, Fig. [1](#phy213238-fig-0001){ref-type="fig"}B) but not during baseline resting and each recovery periods (all *P* \> 0.05, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). On the other hand, ~L~‐NAME in combination with ascorbate reduced CVC throughout the experiment (all *P* ≤ 0.05, Fig. [1](#phy213238-fig-0001){ref-type="fig"}B, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). Further, when compared to the vehicle control site, the difference in CVC with ~L~‐NAME administration was greater in the presence versus absence of co‐administration of ascorbate during exercise (both *P* = 0.01, Fig. [2](#phy213238-fig-0002){ref-type="fig"}B).

### Between‐group comparison {#phy213238-sec-0014}

During both exercise bouts, the magnitude of the reduction in CVC induced by ~L~‐NAME administration alone was similar between groups (both *P* \> 0.05, Fig. [2](#phy213238-fig-0002){ref-type="fig"}). In contrast, the reduction in CVC elicited by ~L~‐NAME combined with ascorbate was greater in the T2D compared with Control group during the second exercise (*P* ≤ 0.05, Fig. [2](#phy213238-fig-0002){ref-type="fig"}). CVC measured at the vehicle control site did not differ between groups during baseline or each exercise, but was higher during each of the two recovery periods in the T2D relative to the Control groups (Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}).

Sweat rate {#phy213238-sec-0015}
----------

A main effect of time and an interaction between time and group were detected for sweat rate (Fig. [3](#phy213238-fig-0003){ref-type="fig"}, Table [3](#phy213238-tbl-0003){ref-type="table-wrap"}, all *P* ≤ 0.05). However, there were no between‐site or between‐group differences in sweat rate throughout the experiment (all *P* \> 0.05, Fig. [3](#phy213238-fig-0003){ref-type="fig"} and Table [3](#phy213238-tbl-0003){ref-type="table-wrap"}).

![Sweat rate evaluated at the last 5 min of the first (Ex 1) and second (Ex 2) 30‐min exercise in older healthy adults (Control, panel A) and those with type 2 diabetes (T2D, panel B). Sweat rate was evaluated at four skin sites treated with either 1) lactated Ringer (vehicle control site), 2) ascorbate, an antioxidant, 3) ~L~‐NAME, a nitric oxide synthase inhibitor, or 4) ascorbate + ~L~‐NAME. Data are expressed as mean ± 95% confidence interval. Values did not differ between sites and groups (all *P* \> 0.07).](PHY2-5-e13238-g003){#phy213238-fig-0003}

###### 

Sweat rate measured during baseline rest (before exercise) and postexercise recovery periods

                         (mg/min/cm^2^)                               
  ---------------------- ---------------- ------------- ------------- -------------
  Control group                                                       
  Vehicle control        0.25 ± 0.05      0.62 ± 0.08   0.70 ± 0.10   0.49 ± 0.07
  Ascorbate              0.26 ± 0.06      0.72 ± 0.08   0.79 ± 0.10   0.60 ± 0.07
  ~L~‐NAME               0.24 ± 0.05      0.69 ± 0.08   0.72 ± 0.10   0.53 ± 0.07
  Ascorbate + ~L~‐NAME   0.26 ± 0.05      0.65 ± 0.11   0.72 ± 0.13   0.52 ± 0.09
  T2D group                                                           
  Vehicle control        0.35 ± 0.07      0.81 ± 0.23   0.94 ± 0.27   0.71 ± 0.18
  Ascorbate              0.34 ± 0.06      0.71 ± 0.16   0.81 ± 0.17   0.64 ± 0.13
  ~L~‐NAME               0.35 ± 0.07      0.77 ± 0.16   0.81 ± 0.15   0.67 ± 0.13
  Ascorbate + ~L~‐NAME   0.34 ± 0.07      0.68 ± 0.20   0.77 ± 0.21   0.63 ± 0.19

All values are expressed as mean ± 95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period. Ascorbate, an antioxidant; ~L~‐NAME, a nitric oxide synthase inhibitor; Rec, recovery; T2D, type 2 diabetes. There were no between‐site and between‐group differences (all *P* \> 0.07).

John Wiley & Sons, Ltd

Cardiovascular and thermal responses {#phy213238-sec-0016}
------------------------------------

A main effect of time was found for heart rate, whereas a main effect of time and an interaction between time and group were measured on mean skin temperature and mean arterial pressure (Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}, all *P* ≤ 0.05). Main effects of time and group and an interaction between time and group were detected for body core temperature (Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}, all *P* ≤ 0.05). Heart rate, mean arterial pressure, and mean skin temperature did not differ between groups throughout the protocol (all *P* \> 0.05) with the exception of lower mean skin temperature during baseline rest in the T2D group (*P* ≤ 0.05, Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}). Body core temperature was higher in the T2D group as compared to the Control group during the second exercise and both recovery periods (all *P* ≤ 0.05, Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}).

###### 

Cardiovascular and body temperature responses measured during baseline rest (before exercise) and the two exercise and recovery periods

                                  Baseline rest                                          Ex 1 at 30 min                                         Rec 1 at 20 min                                                                                     Ex 2 at 30 min                                                                                                                                   Rec 2                                                                                                                                            
  ------------------------------- ------------------------------------------------------ ------------------------------------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------
  Heart rate (bpm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Control group                   71 ± 5                                                 121 ± 10[a](#phy213238-note-0010){ref-type="fn"}       85 ± 9[a](#phy213238-note-0010){ref-type="fn"}                                                      128 ± 12[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}                                                    90 ± 11[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}                                                     86 ± 9[a](#phy213238-note-0010){ref-type="fn"}
  T2D group                       77 ± 8                                                 128 ± 11[a](#phy213238-note-0010){ref-type="fn"}       100 ± 13[a](#phy213238-note-0010){ref-type="fn"}                                                    136 ± 11[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}                                                    106 ± 13[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}                                                    98 ± 11[a](#phy213238-note-0010){ref-type="fn"}
  Mean arterial pressure (mmHg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Control group                   99 ± 4                                                 107 ± 5[a](#phy213238-note-0010){ref-type="fn"}        95 ± 5                                                                                              105 ± 6                                                                                                                                          93 ± 4[a](#phy213238-note-0010){ref-type="fn"}                                                                                                   91 ± 4[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}
  T2D group                       97 ± 5                                                 112 ± 3[a](#phy213238-note-0010){ref-type="fn"}        96 ± 4                                                                                              109 ± 5[a](#phy213238-note-0010){ref-type="fn"}                                                                                                  92 ± 5                                                                                                                                           89 ± 5[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}
  Mean skin temperature (°C)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Control group                   34.94 ± 0.30                                           35.37 ± 0.31[a](#phy213238-note-0010){ref-type="fn"}   34.86 ± 0.33                                                                                        35.35 ± 0.49                                                                                                                                     34.96 ± 0.35                                                                                                                                     34.43 ± 0.35[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}
  T2D group                       34.38 ± 0.24[c](#phy213238-note-0012){ref-type="fn"}   35.50 ± 0.37[a](#phy213238-note-0010){ref-type="fn"}   35.30 ± 0.27[a](#phy213238-note-0010){ref-type="fn"}                                                35.65 ± 0.43[a](#phy213238-note-0010){ref-type="fn"}                                                                                             35.42 ± 0.39[a](#phy213238-note-0010){ref-type="fn"}                                                                                             34.92 ± 0.42[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"}
  Body core temperature (°C)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Control group                   37.01 ± 0.16                                           37.81 ± 0.18[a](#phy213238-note-0010){ref-type="fn"}   37.37 ± 0.10[a](#phy213238-note-0010){ref-type="fn"}                                                37.99 ± 0.24[a](#phy213238-note-0010){ref-type="fn"}                                                                                             37.45 ± 0.14[a](#phy213238-note-0010){ref-type="fn"}                                                                                             37.35 ± 0.13[a](#phy213238-note-0010){ref-type="fn"}
  T2D group                       37.07 ± 0.20                                           37.98 ± 0.19[a](#phy213238-note-0010){ref-type="fn"}   37.81 ± 0.21[a](#phy213238-note-0010){ref-type="fn"} ^,^ [c](#phy213238-note-0012){ref-type="fn"}   38.34 ± 0.23[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"} ^,^ [c](#phy213238-note-0012){ref-type="fn"}   38.18 ± 0.31[a](#phy213238-note-0010){ref-type="fn"} ^,^ [b](#phy213238-note-0011){ref-type="fn"} ^,^ [c](#phy213238-note-0012){ref-type="fn"}   37.87 ± 0.23[a](#phy213238-note-0010){ref-type="fn"} ^,^ [c](#phy213238-note-0012){ref-type="fn"}

Values are mean ± 95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period.

Ex, exercise; Rec, recovery; T2D, type 2 diabetes. bpm, beats per minute.

versus baseline rest (*P* ≤ 0.05).

Ex 1 versus 2 or Rec 1 versus 2 (*P* ≤ 0.05).

versus Control group (*P* ≤ 0.05).

John Wiley & Sons, Ltd

Blood glucose {#phy213238-sec-0017}
-------------

Blood glucose in the T2D group at baseline rest was 8.8 ± 1.2 mmol/L, which decreased to 7.3 ± 0.7 mmol/L at the end of second recovery (*P* = 0.05).

Body weight loss {#phy213238-sec-0018}
----------------

A similar reduction in body weight following exercise in the heat was measured in the Control and T2D groups (1.4 ± 0.1 vs. 1.6 ± 0.3 kg, *P* = 0.27).

Discussion {#phy213238-sec-0019}
==========

We are the first to examine the effect of intradermal ascorbate administration on the regulation of cutaneous vasodilation and sweating in healthy older adults and those with type 2 diabetes exercising in the heat. Our results suggest that during exercise in the heat, ascorbate does not modulate the heat loss responses of cutaneous vasodilation and sweating in both healthy older adults and those with type 2 diabetes. However, we show that NOS is an important contributor to the regulation of cutaneous vasodilation in both groups.

Cutaneous vascular response {#phy213238-sec-0020}
---------------------------

Our results demonstrated no effect of ascorbate on CVC during exercise in the heat in healthy older adults (Fig. [1](#phy213238-fig-0001){ref-type="fig"}A) and this response remained intact during baseline rest as well as post‐exercise recovery (Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). This is in contrast to a previous report by Holowatz et al. ([2006](#phy213238-bib-0019){ref-type="ref"}) in which ascorbate augmented cutaneous vasodilation during passive heating at rest using a water‐perfusion suit. The reason underlying this discrepancy is unknown, but the influence of ascorbate on cutaneous vasodilation during heat stress may differ depending on the level of mean skin temperature. Mean skin temperature in the present study was \~35°C (Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}). In contrast, while mean skin temperature was not reported by Holowatz et al. ([2006](#phy213238-bib-0019){ref-type="ref"}), the temperature measured in their study would likely have been higher (e.g., \~39°C). This is supported by the observations by Brunt et al. ([2013](#phy213238-bib-0002){ref-type="ref"}) using a similar heating procedure with a water‐perfusion suit. Higher skin temperature may induce greater increase in oxidative stress, as a previous report demonstrated that oxidative marker (malondialdehyde) was greater during exercise performed in moderate (32°C) versus cool (12°C) ambient temperature conditions (Sureda et al. [2015](#phy213238-bib-0047){ref-type="ref"}). Hence, the level of oxidative stress in the present study might not have been high enough to affect cutaneous vascular response.

We show for the first time that ascorbate had no effect on cutaneous vasodilation during a passive or exercise‐induced heat stress in older adults with well controlled type 2 diabetes (Fig. [1](#phy213238-fig-0001){ref-type="fig"}B, Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). Although ascorbate may be effective in improving vasodilation response in forearm conduit artery in individuals with type 2 diabetes (Montero et al. [2014](#phy213238-bib-0033){ref-type="ref"}), its influence on markers of oxidative stress (Rytter et al. [2010](#phy213238-bib-0038){ref-type="ref"}) and diabetic complications (Rahimi‐Madiseh et al. [2016](#phy213238-bib-0036){ref-type="ref"}) are relatively minor; a response comparable to that observed on skin vessels in the present study. It should be noted that we employed individuals with well‐controlled type 2 diabetes without the presence of peripheral neuropathy or other diabetic complications. Sweating function may be further impaired in individuals with poor glycemic control and/or the presence of peripheral neuropathy (Luo et al. [2012](#phy213238-bib-0028){ref-type="ref"}; Kenny et al. [2016b](#phy213238-bib-0026){ref-type="ref"}). Thus, the potential exists that the therapeutic benefits of ascorbate in enhancing heat dissipation may be most evident in heat‐vulnerable individuals. However, this possibility requires future scrutiny.

The present study demonstrated that NOS contributes to the regulation of cutaneous vasodilation during exercise in the heat in relatively healthy older adults (Fig. [1](#phy213238-fig-0001){ref-type="fig"}A), which is in accordance with previous reports using passive heating at rest (Holowatz et al. [2003](#phy213238-bib-0018){ref-type="ref"}; Stanhewicz et al. [2012](#phy213238-bib-0043){ref-type="ref"}) and exercise in the heat (Fujii et al. [2015b](#phy213238-bib-0011){ref-type="ref"}, [2016b](#phy213238-bib-0013){ref-type="ref"}). Our results also demonstrate that NOS contributes to cutaneous vasodilation in individuals with T2D during exercise in the heat (Fig. [1](#phy213238-fig-0001){ref-type="fig"}B). Furthermore, the magnitude of the contribution of NOS as evaluated by the ~L~‐NAME‐induced reduction in CVC from the vehicle control site did not differ between groups during exercise in the heat (Fig. [2](#phy213238-fig-0002){ref-type="fig"}). This is consistent with a previous report assessing the response during passive heating at rest (Sokolnicki et al. [2009](#phy213238-bib-0042){ref-type="ref"}). Therefore, our results in combinations with the findings of others (Sokolnicki et al. [2009](#phy213238-bib-0042){ref-type="ref"}) suggest that type 2 diabetes does not blunt NOS‐dependent cutaneous vasodilation irrespective of the nature of the heat stress (i.e., a passive or exercise‐induced heat stress).

Interestingly, we observed that the influence of the combined administration of ascorbate and ~L~‐NAME on cutaneous vasodilation during exercise differed between the Control and T2D groups (Fig. [2](#phy213238-fig-0002){ref-type="fig"}). Specifically, in the Control group, the reduction in CVC induced by the combined administration of ascorbate and ~L~‐NAME was similar to the response measured with the administration of ~L~‐NAME only (Fig. [2](#phy213238-fig-0002){ref-type="fig"}A). In contrast, we showed that the reduction in CVC was greater than that achieved with ~L~‐NAME alone in the T2D group (Fig. [2](#phy213238-fig-0002){ref-type="fig"}B). Based on these results, it appears that in the absence of NO production, ascorbate seems to further attenuate cutaneous vasodilation in individuals with type 2 diabetes. More work is required to assess the mechanisms underpinning this response.

We found that CVC measured at the vehicle control site was higher during the recovery periods in the T2D as compared with the Control group (Table [2](#phy213238-tbl-0002){ref-type="table-wrap"}). It is unclear why the T2D group exhibited a higher CVC response during the postexercise recovery period only, but a higher body core temperature and therefore greater thermal drive may be involved (Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}). In contrast to our findings, previous studies have shown that type 2 diabetes attenuates cutaneous vasodilation during passive heating at rest (Wick et al. [2006](#phy213238-bib-0049){ref-type="ref"}; Sokolnicki et al. [2009](#phy213238-bib-0042){ref-type="ref"}). However, these previous studies employed a different heat stress protocol (whole‐body heating with a water‐perfused suit) that makes a direct comparison of responses difficult.

Sweating response {#phy213238-sec-0021}
-----------------

We found that ascorbate did not influence sweat rate relative to the vehicle control site during exercise (Fig. [3](#phy213238-fig-0003){ref-type="fig"}) as well as during resting and postexercise recovery (Table [3](#phy213238-tbl-0003){ref-type="table-wrap"}) in the heat in either group. Hence, ascorbate does not appear to enhance sweating in healthy older adults and those with type 2 diabetes under the conditions examined. On the other hand, in keeping with our previous studies (Stapleton et al. [2014](#phy213238-bib-0045){ref-type="ref"}; Fujii et al. [2015b](#phy213238-bib-0011){ref-type="ref"}, [2016b](#phy213238-bib-0013){ref-type="ref"}), we confirmed no role for NOS in the regulation of sweating during exercise in the heat in healthy older adults (Fig. [3](#phy213238-fig-0003){ref-type="fig"}), which is in contrast to findings in younger adults (Welch et al. [2009](#phy213238-bib-0048){ref-type="ref"}; Stapleton et al. [2014](#phy213238-bib-0045){ref-type="ref"}; Fujii et al. [2016b](#phy213238-bib-0013){ref-type="ref"}). Since no contribution of NOS to sweating during exercise in the heat was also observed in the T2D group (Fig. [3](#phy213238-fig-0003){ref-type="fig"}), the age‐related reduction in NOS‐dependent sweating is present irrespective of the presence of type 2 diabetes. While the mechanisms underpinning these findings are currently unclear, increased oxidative stress associated with aging might not be involved given that ascorbate perfusion did not influence the sweating response when administered alone or in combination with ~L~‐NAME. Further research is warranted to delineate the mechanisms mediating the age‐related attenuation in NOS‐dependent sweating during exercise in the heat.

As with cutaneous vasodilation, our results demonstrate that type 2 diabetes does not modulate local forearm sweat rate during exercise in the heat (Fig. [3](#phy213238-fig-0003){ref-type="fig"}), which is consistent with our previous work (Kenny et al. [2013](#phy213238-bib-0023){ref-type="ref"}). Noteworthy, the same study showed that whole‐body sweating during exercise is indeed attenuated in individuals with T2D (Kenny et al. [2013](#phy213238-bib-0023){ref-type="ref"}). Therefore, it is likely that the influence of type 2 diabetes on sweating during exercise in the heat is site‐specific. Attenuations in whole‐body sweating and thus heat loss is indirectly supported by the fact that we observed a greater increase in body core temperature in the T2D versus Control group after the first exercise (Table [4](#phy213238-tbl-0004){ref-type="table-wrap"}). Further studies are required to evaluate regional responses associated with diabetes‐related modulation of the sweating response.

Considerations {#phy213238-sec-0022}
--------------

We did not directly assess levels of ascorbate/vitamin C and oxidative stress in the Control and T2D groups. It is therefore possible that our findings are simply a product of including participants in both groups with relatively similar levels of systemic inflammation/oxidative stress. By design, we examined the influence of local ascorbate infusion in individuals with well‐controlled type 2 diabetes. It is possible however, that relative to their healthy counterparts, differences in levels of systemic inflammation/oxidative stress may be more pronounced in individuals with type 2 diabetes who have poor glycemic control and or who are affected by diabetes‐related complications. Factors such as medication use may also play an important role in modulating this response. However, given our T2D participants were on several different medications, our results do not provide information pertaining to which medication may have influenced the observed findings.

Perspectives and significance {#phy213238-sec-0023}
-----------------------------

Older individuals are at greater risk of heat‐related injuries (Worfolk [2000](#phy213238-bib-0050){ref-type="ref"}; Kenney et al. [2014](#phy213238-bib-0021){ref-type="ref"}; Kenny et al. [2016b](#phy213238-bib-0026){ref-type="ref"}), and type 2 diabetes can exacerbate this risk (Semenza et al. [1999](#phy213238-bib-0039){ref-type="ref"}; Kenny et al. [2016b](#phy213238-bib-0026){ref-type="ref"}). Hence the development of interventions to augment heat dissipation and circumvent potentially dangerous increases in body core temperature is of the utmost importance. Based on the results obtained in this study, we show that ascorbate does not improve the heat loss responses through cutaneous vasodilation and sweating in healthy older adults and those with type 2 diabetes during exercise as well as resting before and after exercise in the heat. Therefore, oral supplementation of ascorbate may not be an effective therapeutic strategy to reverse age‐ and diabetes‐related impairments in heat loss in these at‐risk populations.

Conclusion {#phy213238-sec-0024}
==========

We show that intradermal administration of ascorbate does not affect cutaneous vasodilation and sweating during exercise in the heat in both healthy older adults and those with type 2 diabetes. We also show that in both groups, NOS contributes to the regulation of cutaneous perfusion during exercise in the heat.
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